Should prednisolone be first-line therapy for acute gout?

The Lancet

Volumn 372, Issue 9646, 2008, Pages 1301-

  Richette, Pascal ^a   Bardin, Thomas ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CORTICOSTEROID DERIVATIVE; GLUCOCORTICOID; GLUCOSE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ACUTE DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LETTER; LOW DRUG DOSE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; STEROID THERAPY;

EID: 53349161025     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61548-2     Document Type: Letter

References (5)

1. Janssens H.J., Janssen M., van de Lisdonk E.H., van Riel P.L., and van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 371 (2008) 1854-1860
2. Rott K.T., and Agudelo C.A. Gout. JAMA 289 (2003) 2857-2860
3. Rull M., Clayburne G., Sieck M., and Schumacher H.R. Intra-articular corticosteroid preparations: different characteristics and their effect during inflammation induced by monosodium urate crystals in the rat subcutaneous air pouch. Rheumatology 42 (2003) 1093-1100
4. Zhang W., Doherty M., Bardin T., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65 (2006) 1312-1324
5. Morris I., Varughese G., and Mattingly P. Colchicine in acute gout. BMJ 327 (2003) 1275-1276